Primary (AL) amyloidosis is the most prevalent type of systemic amyloidosis, and management of this disease has evolved through the years from supportive care to aggressive treatments that include ...

Hodgkin's Disease Survivors More Fatigued Than the General Population PURPOSE: Primary systemic amyloidosis is an immunoglobulin deposition disorder in which insoluble light chains cause organ ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Committee for Medicinal Products for Human Use (CHMP) ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the HELIOS-A Phase 3 study of vutrisiran, an ...

Please provide your email address to receive an email when new articles are posted on . Alnylam announced top-line results of a trial showing that patisiran improved 6-minute walk test distance in ...

Systemic light chain (AL) amyloidosis is a rare and life-threatening disorder characterized by the deposition of misfolded immunoglobulin light chains as insoluble amyloid fibrils in various tissues ...

− Echocardiographic and Cardiac Biomarker Data From the HELIOS-B Study Presented Today Support the Potential of Vutrisiran in ATTR-CM – − Vutrisiran Significantly Improved Echocardiographic ...

The MarketWatch News Department was not involved in the creation of this content. MISSISSAUGA, ON, Dec. 16, 2025 /CNW/ - Alnylam Canada ULC is pleased to announce that Health Canada has issued a ...

Cardiac amyloidosis, or "stiff heart syndrome," is a rare manifestation of amyloidosis, which carries the worst prognosis of any involved organ. Researchers have developed a new technique that they ...

Patients beginning lung cancer treatment demonstrated a high prevalence of atherosclerosis, which suggests that they may benefit from calcium scoring, new data showed. According to a presentation ...